SAMSON, SAMS and nocebo effects
- 12 February 2021
- journal article
- editorial
- Published by Elsevier BV in Atherosclerosis
- Vol. 321, 45-46
- https://doi.org/10.1016/j.atherosclerosis.2021.02.005
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditionsJournal of Cachexia, Sarcopenia and Muscle, 2018
- Statin-Associated Muscle Disease: Advances in Diagnosis and ManagementNeurotherapeutics, 2018
- Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractEuropean Heart Journal, 2018
- Management of Statin Intolerance in 2018: Still More Questions Than AnswersAmerican Journal of Cardiovascular Drugs, 2018
- Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseThe Lancet, 2017
- Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further CountriesCardiovascular Drugs and Therapy, 2017
- Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial InfarctionJournal of Invasive Cardiology, 2017
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementEuropean Heart Journal, 2015
- Nocebo Effect in Randomized Clinical Trials of Antidepressants in Children and Adolescents: Systematic Review and Meta-AnalysisFrontiers in Behavioral Neuroscience, 2014
- Effect of Statins on Skeletal Muscle FunctionCirculation, 2013